Physician profile
Robert C Chu
NPI 1255313599
$29,782.48
in general payments reported to CMS, 2019-2025
20 companies · $4,406 in 2025
The $4,406 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,558 · 2020: $2,774 · 2021: $6,354 · 2022: $5,137 · 2023: $2,034 · 2024: $1,519 · 2025: $4,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,037 · Consulting Fee: $2,875 · Entertainment: $47.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,036.70 |
| Consulting Fee | $2,875.00 |
| Entertainment | $47.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $16,999.48 | 2019-2025 | Precision 1, Dailies Total1, Precision 7 |
| Alcon Research LLC | $5,961.45 | 2021-2025 | |
| Sight Sciences, INC. | $4,285.85 | 2019-2025 | Tearcare System, Omni Surgical System |
| Biotissue Holdings INC. | $787.07 | 2019-2025 | |
| Carl Zeiss Meditec USA, INC. | $369.75 | 2021-2024 | Forum |
| Bausch & Lomb Americas INC. | $319.90 | 2022-2025 | Miebo, Xiidra, Infuse |
| Optos, INC. | $304.55 | 2020-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Horizon Therapeutics Plc | $137.23 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $110.78 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $99.11 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $91.03 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $74.44 | 2019-2024 | |
| Ocular Therapeutix, INC. | $65.62 | 2025 | Dextenza |
| Allergan, INC. | $34.63 | 2020-2022 | |
| New World Medical,INC. | $33.46 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $25.83 | 2023 | |
| Abbvie INC. | $24.87 | 2025 | |
| Eyepoint US, INC. | $23.64 | 2020 | |
| Eyevance Pharmaceuticals LLC | $18.99 | 2019 | |
| Harrow Eye, LLC | $14.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.